# Lopinavir/Ritonavir in Combination With Saquinavir Mesylate or Lamivudine/Zidovudine to Explore Metabolic Toxicities in Antiretroviral HIV-Infected Subjects

> **NCT00043953** · PHASE2 · COMPLETED · sponsor: **Abbott** · enrollment: 30 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Lopinavir/ritonavir
- **DRUG:** Saquinavir mesylate
- **DRUG:** Lamivudine/zidovudine

## Key facts

- **NCT ID:** NCT00043953
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-08
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2007-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00043953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00043953, "Lopinavir/Ritonavir in Combination With Saquinavir Mesylate or Lamivudine/Zidovudine to Explore Metabolic Toxicities in Antiretroviral HIV-Infected Subjects". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00043953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*